Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of Billionaire Ken Fisher’s 15 Most Notable Moves for 2026.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a relatively recent addition to the 13F portfolio of Fisher Asset Management. The fund first disclosed a stake in the firm in filings for the second quarter of 2024, comprising close to 12,000 shares purchased at an average price of more than $24. In the ensuing six quarters, the fund has aggressively added to this stake, with notable additions of 941%, 238%, and 133% in late 2024 and early 2025. The latest increase is close to 25%. These numbers matter because Ken Fisher is very guarded about investments in pharma firms. In 2023, he said that biotech is a very specialized area, and most of the companies in this domain are small and not particularly profitable.

A cursory glance at the latest earnings of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shows that it is not any biotech firm. In the first fiscal quarter of 2026, it beat market estimates on earnings per share and revenue. During the earnings call, the CEO of the firm pointed to key upcoming events, including the Q3 2026 readout of Phase III SHASTA-3 and SHASTA-4 studies of plozasiran in patients with SHTG, which, per the CEO, has the potential to be a $3 billion to $4 billion commercial opportunity.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) develops medicines for the treatment of intractable diseases in the United States. The pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies and Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials.

While we acknowledge the potential of ARWR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.